Acurx Pharmaceuticals Inc. Unveils Presentation on Advancing New Class of Antibiotics to Phase 3 Trials Targeting Priority Pathogens and Addressing Antimicrobial Resistance
Reuters
Aug 28
Acurx Pharmaceuticals Inc. Unveils Presentation on Advancing New Class of Antibiotics to Phase 3 Trials Targeting Priority Pathogens and Addressing Antimicrobial Resistance
Acurx Pharmaceuticals Inc. has announced progress in advancing a new class of antibiotics to Phase 3 trials, targeting WHO and CDC "Priority Pathogens" while addressing growing concerns related to antimicrobial resistance $(AMR)$. The company's lead antibiotic program, ibezapolstat, is designed to treat _C. difficile_ Infection (CDI) and has demonstrated promising results with a 96% cure rate and no recurrence at 30 and 90-day follow-ups during Phase 2 trials. The antibiotics work by targeting the polymerase IIIC enzyme, a novel mechanism of action that has shown clinical validation. Additionally, Acurx Pharmaceuticals is preparing to evaluate ibezapolstat in patients with multiple recurrences of CDI and resistance to current standards of care. The company's commercial supply is manufactured in the U.S., maintaining a "Made In America" policy. Acurx Pharmaceuticals holds $6.1 million in cash on hand. You can access the full presentation through the link below.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Acurx Pharmaceuticals Inc. published the original content used to generate this news brief on August 28, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.